UBS casts doubt on Diageo's US recovery ahead of strategy update

What happened

UBS warns that Diageo's upcoming capital markets day in August may fail to reassure investors about a US recovery, arguing expectations remain overly optimistic. The bank's skepticism adds to the existing headwinds of flat revenue, a 27.8% drop in reported operating profit, and elevated leverage of 3.5x net debt/EBITDA. Despite a 32% share price decline over 12 months, the stock still trades 35% above a conservative DCF estimate, implying limited margin of safety. Leadership is in flux with an interim CEO and CFO, while execution risks from large transformation programs linger. The news reinforces the view that near-term fundamentals remain challenged, making a catalyst-driven turnaround uncertain.

Implication

The UBS warning underscores that Diageo's US spirits recovery, a key pillar of the bull case, may take longer or be less robust than hoped. Investors should watch the August capital markets day for concrete evidence of cost savings, deleveraging progress, and realistic organic growth guidance. Without a clear, achievable plan, the stock's current valuation above DCF offers little safety. A permanent CEO appointment and early signs of Accelerate program delivery would be positive, but near-term patience is warranted given execution risk and analyst skepticism.

Thesis delta

The already cautious DeepValue thesis is further darkened by UBS's explicit pessimism on US spirits recovery. Previously, the wait stance assumed a possible turn with clearer strategy and deleveraging; now the bar is higher, as even the anticipated reset may fail to lift sentiment. The probability of a near-term positive catalyst has diminished, tilting the risk-reward slightly more negative.